bortezomib + oxaliplatin

Bortezomib + oxaliplatin is an investigational combination therapy consisting of two small molecule chemotherapeutic agents: bortezomib, a reversible proteasome inhibitor, and oxaliplatin, a platinum-based DNA crosslinking agent. Bortezomib inhibits the 26S proteasome, disrupting protein degradation and leading to cell cycle arrest and apoptosis in cancer cells. Oxaliplatin forms DNA adducts that inhibit DNA replication and transcription, resulting in cytotoxicity. The rationale for combining these drugs is based on potential synergy—bortezomib may enhance the effects of platinum-induced DNA damage by interfering with cellular repair mechanisms. This combination has been studied primarily in patients with advanced solid tumors (including colorectal cancer) to assess safety, tolerability (notably neurotoxicity), pharmacokinetics, and preliminary efficacy[1][2][3].